Aurigen Medical 5

AuriGen Medical is transforming stroke risk in patients with atrial fibrillation (AF) through its next-generation heart implant, Zenith. Following 100% technical success and zero complications in First-in-Human trials, AuriGen has recently won a 2nd DTIF non-dilutive Grant of €6.3M and strong investor backing to accelerate its next growth phase. Final €1M available in the Pre-Series A bridge round. Invest now to join our mission redefining stroke prevention in AF patients.

Key Highlights (short version)

• Breakthrough Clinical Validation: 100% technical success and zero complications in First-in-Human trial, confirming Zenith’s potential to transform stroke risk reduction in AF patients.
• Recently won €6.3M Non-Dilutive Funding: Backed by Ireland’s DTIF, accelerating AuriGen’s next growth phase.
• Clinician-Led Investment: Several leading European cardiologists invested directly, reinforcing deep clinical confidence.
• Expanding Market: LAAO market growing from $2B to $10B by 2032 (25–30% CAGR); Boston Scientific reports 28% YoY growth.
• Next-Gen Device: Fully repositionable with real-time seal verification, a safer, simpler, and more precise solution designed to meet the complex needs of high-stroke-risk patients.
• Strategic Momentum: Multiple venture investors and two global MedTech strategics actively engaged, reflecting strong market confidence.
• Value Inflection Ahead: DTIF grant and bridge funding enable early Series A activities, accelerating progress and bringing forward the next major value inflection for shareholders.